Leerink Partners Thinks Zimmer Biomet Holdings’ Stock is Going to Recover

Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Zimmer Biomet Holdings (ZBHResearch Report) on January 24 and set a price target of $150.00. The company’s shares closed last Thursday at $118.77, close to its 52-week low of $108.47.

According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zimmer Biomet Holdings with a $129.41 average price target, which is an 8.7% upside from current levels. In a report issued on February 8, Loop Capital Markets also maintained a Buy rating on the stock with a $140.00 price target.

See the top stocks recommended by analysts >>

Zimmer Biomet Holdings’ market cap is currently $24.81B and has a P/E ratio of 62.34.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.

Read More on ZBH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed